Compare INTT & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | ORGO |
|---|---|---|
| Founded | 1981 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 127.6M |
| IPO Year | 1997 | 2016 |
| Metric | INTT | ORGO |
|---|---|---|
| Price | $14.16 | $0.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $20.00 | $2.00 |
| AVG Volume (30 Days) | 122.2K | ★ 929.1K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ 0.06 | N/A |
| Revenue | $66,801,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $22.35 | N/A |
| Revenue Next Year | $7.07 | $37.55 |
| P/E Ratio | $263.00 | ★ N/A |
| Revenue Growth | ★ 66.06 | 17.04 |
| 52 Week Low | $7.07 | $0.81 |
| 52 Week High | $20.00 | $7.08 |
| Indicator | INTT | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 16.25 |
| Support Level | $12.54 | N/A |
| Resistance Level | $15.25 | $2.57 |
| Average True Range (ATR) | 0.95 | 0.08 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 49.87 | 1.64 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.